読み込み中
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
前日終値
$29.89
+$0.59 · +2.01%
市場前
$29.5437
−$0.3463 · -1.16%
10月12日 7:27 ET
日中の時刻はETです。市場データは遅延する場合があります。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日中レンジ
現在 $29.89
52週レンジ
現在 $29.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
10
著しい割高
センチメント
59
まちまち
リスク
34
中程度のリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
日中レンジ
現在 $29.89
52週レンジ
現在 $29.89
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 150万 USD | 702万 USD | 688.3万 USD | 235.7万 USD | 465.1万 USD |
| 売上原価 | — | 1.64億 USD | 1.18億 USD | 8225.8万 USD | 5331.1万 USD |
| 粗利益 | 150万 USD | −1.57億 USD | −1.11億 USD | −7990.1万 USD | −4866万 USD |
| 研究開発 | 2.45億 USD | 1.64億 USD | 1.18億 USD | 8225.8万 USD | 5681.1万 USD |
| 販売・一般管理 | 4380万 USD | 3854.8万 USD | 3091.4万 USD | 2719.5万 USD | 2048.8万 USD |
| 営業費用 | 2.89億 USD | 3854.8万 USD | 4341.4万 USD | 3533.3万 USD | 2258.3万 USD |
| 受取利息 | 2861万 USD | 3721.5万 USD | 1311.3万 USD | 290.9万 USD | 50.5万 USD |
| 減価償却費と償却費 | 338万 USD | 317.7万 USD | 300.8万 USD | 289.6万 USD | 306.8万 USD |
| 営業利益 | −2.87億 USD | −1.95億 USD | −1.55億 USD | −1.15億 USD | −7124.3万 USD |
| 純利益 | −2.59億 USD | −1.58億 USD | −1.41億 USD | −1.12億 USD | −7051.1万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$66.80
上昇余地（123.49%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年2月11日 | 1:15 | — | — |
株式分割 | 2008年3月10日 | 1:12 | — | — |
発効済み 2019年2月11日
1:15
発効済み 2008年3月10日
1:12
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI9896.18万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM6020.33万0.08%787.4億 USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4760.76万0.48%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF3620.64万0.04%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO1780.49万0.10%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO1712.99万0.12%139.17億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS1369.31万0.04%338.69億 USD0.31%$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA1217.64万0.06%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
